Last reviewed · How we verify
NCT04845880
SARS Cov_2 Incidence of Healthy Health Workers
NA trial testing Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2 in SARS COV-2 IgG Levels on Health Workers in 182 participants. Completed in 1 April 2021.
1 March 2021
Quick facts
| Lead sponsor | Baskent University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 182 |
| Start date | 1 October 2020 |
| Primary completion | 1 March 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Conditions studied
- SARS COV-2 IgG Levels on Health Workers — all drugs for SARS COV-2 IgG Levels on Health Workers →
Sponsor
Baskent University
Who can join
Adults 18 to 65, any sex, with SARS COV-2 IgG Levels on Health Workers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04845880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Baskent University trials
Trials by the same sponsor.
- NCT07521982 — Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healt · not yet recruiting
- NCT07202650 — THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME · NA · recruiting
- NCT07394907 — The Effectiveness of Gamified Metaverse-Based Training on Patient Safety for Nursing Students · NA · not yet recruiting
- NCT07395284 — The Effect of Gamified Metaverse-Based Training on Nursing Students' Self-Efficacy and Metaverse Perception Regarding Pr · NA · not yet recruiting
- NCT07385339 — Comfort Communication Model Intervention for Burn Pain and Pain Anxiety · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04845880 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baskent University
- Last refreshed: 15 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04845880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing